Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIKHIL V INAMDAR

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1093723132
CMS profile
230365
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,008.25

42 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,008.25 42

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIKHIL V INAMDAR

NPI 1093723132 · CMS profile ID 230365

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093723132?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIKHIL V INAMDAR, NPI 1093723132, CMS profile ID 230365. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093723132?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NIKHIL V INAMDAR, NPI 1093723132, CMS profile ID 230365. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093723132?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NIKHIL V INAMDAR, NPI 1093723132, CMS profile ID 230365, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093723132?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

42 matching records · $1,008.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 42 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–42 of 42.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.5612/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057399669 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.4212/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057131155 CMS
ABBVIE INC. $17.0912/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531905 CMS
Gilead Sciences, Inc. $21.6912/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025756905 CMS
ABBVIE INC. $11.7711/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531903 CMS
ABBVIE INC. $16.5411/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531901 CMS
ABBVIE INC. $15.5711/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531899 CMS
ABBVIE INC. $24.3711/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531895 CMS
ABBVIE INC. $3.3111/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531897 CMS
Ironwood Pharmaceuticals, Inc $14.2610/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045571851 CMS
INTERCEPT PHARMACEUTICALS, INC. $19.2710/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053828019 CMS
ABBVIE INC. $5.0209/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531893 CMS
ABBVIE INC. $19.1309/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531891 CMS
INTERCEPT PHARMACEUTICALS, INC. $24.9209/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053828015 CMS
ABBVIE INC. $28.2509/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531889 CMS
Axonics, Inc. $48.6209/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051814749 CMS
ABBVIE INC. $16.5809/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531887 CMS
PFIZER INC. $32.4308/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050595983 CMS
Axonics, Inc. $37.5508/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051814691 CMS
ABBVIE INC. $25.4407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531885 CMS
Celgene Corporation $20.0907/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016366375 CMS
ABBVIE INC. $21.1507/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531883 CMS
ABBVIE INC. $23.3806/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531881 CMS
Celgene Corporation $19.5206/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016366355 CMS
Celgene Corporation $23.1905/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016366333 CMS
PFIZER INC. $30.9605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049533003 CMS
Celgene Corporation $19.8104/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016366315 CMS
ABBVIE INC. $17.2404/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531879 CMS
Boston Scientific Corporation $21.3604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022030467 CMS
Celgene Corporation $23.6103/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016366309 CMS
Ardelyx, Inc. $20.9803/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052949577 CMS
Celgene Corporation $19.8003/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016366269 CMS
RedHill Biopharma Inc. $15.3302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996663441 CMS
RedHill Biopharma Inc. $13.0002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996663347 CMS
ABBVIE INC. $13.4402/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531877 CMS
Janssen Biotech, Inc. $19.7902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988411397 CMS
RedHill Biopharma Inc. $23.1002/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996693721 CMS
ABBVIE INC. $21.4302/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531875 CMS
Janssen Scientific Affairs, LLC $148.9001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988466913 CMS
Braintree Laboratories, Inc. $21.1001/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006450485 CMS
ABBVIE INC. $22.5701/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997531873 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.7101/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055412971 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $254.33 18
PY2020 $67.35 4
PY2021 $70.92 5
PY2022 $780.77 31
PY2023 $1,008.25 42
PY2024 $720.37 36
PY2025 $854.66 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $35,696.45 10
PY2024 Principal investigator $19,138.20 3
PY2023 Principal investigator $12,650.20 5
PY2022 Principal investigator $17,963.35 8
PY2021 Recipient $480.00 1
PY2021 Principal investigator $128,158.76 43
PY2020 Principal investigator $146,255.72 108
PY2019 Recipient $18,259.37 8
PY2019 Principal investigator $239,865.67 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

108 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $1,607.40 12/30/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-000 No dispute reported 06/30/2026 721203139
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311871
Principal investigator 1 AbbVie Inc. $300.00 12/03/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-066 No dispute reported 06/30/2026 721199305
Principal investigator 1 AbbVie Inc. $300.00 12/03/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-067 No dispute reported 06/30/2026 721199307
Principal investigator 1 Roche Products Limited $300.00 12/03/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 857151031
Principal investigator 1 AbbVie Inc. $300.00 11/18/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M14-433 No dispute reported 06/30/2026 721196051
Principal investigator 1 AbbVie Inc. $300.00 11/18/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M14-430 No dispute reported 06/30/2026 721196053
Principal investigator 1 Allergan, Inc. $4,208.50 11/16/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721308259
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $84.60 11/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737092299
Principal investigator 1 AbbVie Inc. $1,205.10 10/30/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-000 No dispute reported 06/30/2026 721193833
Principal investigator 1 AbbVie Inc. $9,085.20 10/29/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M14-431 No dispute reported 06/30/2026 721193219
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721305063
Principal investigator 1 Allergan, Inc. $1,366.10 10/19/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $774.90 10/08/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737089935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $420.30 09/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737087799
Principal investigator 1 AbbVie Inc. $1,404.90 09/03/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-000 No dispute reported 06/30/2026 721184875
Principal investigator 1 Allergan, Inc. $831.25 08/19/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291469
Principal investigator 1 Allergan, Inc. $1,841.10 07/20/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285535
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $774.90 06/23/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737083941
Principal investigator 1 AbbVie Inc. $2,373.75 06/22/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-000 No dispute reported 06/30/2026 721171761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,342.00 06/11/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737082933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $936.80 06/11/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737082935
Principal investigator 1 Allergan, Inc. $1,063.05 05/25/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721277005
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 05/14/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737081239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $0.30 05/14/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737081241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/24/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737077907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30.00 04/24/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737077909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,270.00 04/09/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737076907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $399.00 04/09/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737076909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $270.00 04/09/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737076911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 04/09/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737076915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 04/09/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737076917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $336.00 04/09/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737076919
Principal investigator 1 AbbVie Inc. $1,411.65 03/31/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-000 No dispute reported 06/30/2026 721159345
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $962.00 03/13/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737074205
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $314.70 03/13/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737074207
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.00 03/13/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737074209
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262819
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $696.60 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,007.00 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073969
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $861.00 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $861.00 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073973
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $359.90 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073979
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.00 03/10/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737073981
Principal investigator 1 AbbVie Inc. $450.00 03/03/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-000 No dispute reported 06/30/2026 721154287
Principal investigator 1 Eli Lilly and Company $2,975.00 03/02/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 728749567
Principal investigator 1 AbbVie Inc. $372.60 02/28/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-006 No dispute reported 06/30/2026 721153219
Principal investigator 1 Eli Lilly and Company $28.24 02/27/2020 Non-covered Recipient Entity
HCA HOUSTON HEALTHCARE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) No dispute reported 06/30/2026 728744371
Principal investigator 1 Eli Lilly and Company $26.20 02/26/2020 Non-covered Recipient Entity
HCA HOUSTON HEALTHCARE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 728738345
Principal investigator 1 Allergan, Inc. $3,761.05 02/17/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721258029
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,711.70 02/12/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737072097
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.00 02/10/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737070063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.20 02/10/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737070065
Principal investigator 1 AbbVie Inc. $9,404.70 02/03/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
M16-006 No dispute reported 06/30/2026 721149275
Principal investigator 1 Eli Lilly and Company $1,394.73 01/28/2020 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 728750393
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,190.00 01/17/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737068023
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $861.00 01/17/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737068025
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $467.00 01/17/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737068027
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $168.50 01/17/2020 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737068029
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,449.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066819
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,458.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,449.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,449.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,449.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,449.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,449.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,342.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,342.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,458.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,305.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,190.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,190.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,190.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,007.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,007.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,007.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,458.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,007.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $861.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $861.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066881
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066891
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $843.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,458.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066899
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066901
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $646.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $467.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.00 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,619.90 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737066921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $774.90 01/02/2020 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737067041

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $30,371.83 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $30,371.83 1
PY2022 Amount invested $345.82 1
PY2022 Value of interest $1,907.69 1
PY2021 Amount invested $1,247.84 1
PY2021 Value of interest $1,560.22 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $30,371.83 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124819083
PY2023 GastroGPO, LLC $0.00 $30,371.83 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730035
PY2022 GastroGPO, LLC $345.82 $1,907.69 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955000235
PY2021 GastroGPO, LLC $1,247.84 $1,560.22 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854913835